Back to School: How biopharma can reboot drug development. Access exclusive analysis here

GI-5005: Additional Phase IIb data

A retrospective analysis of 96 treatment-naïve patients from an open-label Phase IIb trial showed that GI-5005 plus SOC ( Copegus ribavirin and Pegasys peginterferon alfa-2a) led to

Read the full 274 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE